Clinical Trial Update: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale [Phase 3]

View source ↗

Summary

Biogen's Phase 3 trial of BIIB122 for early Parkinson's disease with LRRK2 variants was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIIB122

Snippet

Sponsor: Biogen | Conditions: Parkinson Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-06-26